Specifically, rapamycin treatment significantly reduced KPNA2 expression through the acceleration of KPNA2 protein turnover and the suppression of Dp1/E2F1 expression in NSCLC cells. The gene discussed is KPNA2; the disease is non-small cell lung carcinoma.